June 2024 – Page 9 – Goldea Capital

Earth Alive Announces Election of Directors

Written by Customer Service on June 28, 2024. Posted in Public Companies.

MONTREAL, June 28, 2024 (GLOBE NEWSWIRE) — Earth Alive Clean Technologies Inc. (TSXV: EAC – “Earth Alive” or the “Company”), a company that develops, manufactures and distributes state-of-the-art, environmentally-sound proprietary microbial solutions and products, announces today that at its Annual General Meeting of Shareholders held on June 27, 2024, all directors nominated in the 2024 management proxy circular were elected. A total of 239,335,786 common shares or 41.38% of the Company’s issued and outstanding common shares were represented in person or by proxy at the meeting. Detailed results are as follows: Nominee Votes For % of Votes For Votes Against % ofVotes Against Robert Blain 234,445,786 99.84 386,000 0.16 Erik Bomans 234,404,436 99.82 427,350 0.18 David Colon 234,405,786 99.82 426,000 0.18 Valérie Renard 234,445,786 99.84 386,000 0.16 Nicolas...

Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Written by Customer Service on June 28, 2024. Posted in Public Companies.

Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in both relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma TARRYTOWN, N.Y., June 28, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy. The European Commission is expected to announce a final decision in the coming months. FL and DLBCL are the two most common subtypes of B-cell non-Hodgkin lymphoma (B-NHL)....

Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors

Written by Customer Service on June 28, 2024. Posted in Public Companies.

BOSTON, June 28, 2024 (GLOBE NEWSWIRE) — Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its board of directors. Dr. Tatsis currently serves as executive vice president, chief regulatory and quality officer, of Vertex Pharmaceuticals. Ms. Morrison currently serves as chief executive officer and director of Q32 Bio Inc. “We are thrilled to have Nia and Jodie join Verve’s board of directors, lending their decades of impressive experience leading and advising pharmaceutical and biotech companies through critical stages in drug development, manufacturing, and commercialization,” said Sekar Kathiresan, M.D., co-founder and chief executive officer...

23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel

Written by Customer Service on June 28, 2024. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker testing and risk prediction, today announced a strategic collaboration to pilot Nightingale Health’s clinically-validated and cost-effective blood metabolomics panel with a cohort of 23andMe members. Nightingale’s Remote Health Check accurately measures dozens of biomarkers from a single blood sample, including cholesterols, apolipoproteins and fatty acids like omega-3. Many of these blood biomarkers have established clinical relationships to disease and can help guide important lifestyle interventions – such as diet and exercise. This pilot marks an important milestone in making blood testing more efficient and accessible. 23andMe...

OTC Markets Group Welcomes Endo, Inc. to OTCQX

Written by Customer Service on June 28, 2024. Posted in Public Companies.

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Endo, Inc. (OTCQX: NDOI), a diversified specialty pharmaceutical company, has qualified to trade on the OTCQX® Best Market. Endo, Inc. begins trading today on OTCQX under the symbol “NDOI.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. Trading on the OTCQX Market offers companies efficient, cost-effective access to the U.S. capital markets. Streamlined market requirements for OTCQX are designed to help companies lower the cost and complexity of being publicly traded, while providing transparent trading for their investors. To qualify for OTCQX, companies must meet high financial...

Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Written by Customer Service on June 28, 2024. Posted in Public Companies.

SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today that the Company will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, as part of the annual reconstitution of the Russell stock indexes, effective today. “We are pleased to have earned inclusion in the Russell indexes, among the most widely used benchmarks for small-cap stocks,” said Dr. Aoife Brennan, CEO of Eliem Therapeutics. “This is an important milestone for Eliem as we continue to build momentum and develop our world-class science and innovation aimed at harnessing the extraordinary potential of TNT119, a potent, CD19-targeted antibody with enhanced effector function, that we believe has the potential across a broad range of autoimmune diseases.” Membership...

Plug to Receive Federal Clean Hydrogen Production Tax Credit at Georgia Hydrogen Facility

Written by Customer Service on June 28, 2024. Posted in Public Companies.

LATHAM, N.Y., June 28, 2024 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, which began commercial operation of its electrolytic hydrogen facility in Woodbine, Ga. earlier this year, intends to recognize the benefits of the Inflation Reduction Act’s (IRA) Section 45V Credit for the Production of Clean Hydrogen (PTC) in its forthcoming quarterly financial reports. Plug will be one of the first producers of clean hydrogen in the United States that anticipates utilizing this new incentive enacted by an Act of Congress and signed by President Biden. The PTC offers a production credit of up to $3.00 per kilogram for clean hydrogen (H2) produced in the U.S., providing a substantial financial incentive for hydrogen production in the U.S, substantially...

Asset Entities Inc. Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price

Written by Customer Service on June 28, 2024. Posted in Public Companies.

DALLAS, June 28, 2024 (GLOBE NEWSWIRE) — Asset Entities Inc. (“Asset Entities” or the “Company”) (NASDAQ: ASST), a provider of digital marketing and content delivery services across Discord and other social media platforms, and a Ternary Payment Platform company, today announced a 1-for-5 reverse stock split (the “Reverse Stock Split”) of its class A common stock, $0.0001 par value per share (the “Class A Common Stock”), and its class B common stock, $0.0001 par value per share (the “Class B Common Stock” and together with the Class A Common Stock, the “common stock”). The Company’s Class B Common Stock will continue to trade on The Nasdaq Capital Market tier of The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “ASST” and will begin trading on a split-adjusted basis when the market opens on Tuesday, July 2, 2024. The new...

Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma

Written by Customer Service on June 28, 2024. Posted in Public Companies.

First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step in Global Expansion to Address >20,000 Patients Annually with Previously Treated Advanced Melanoma SAN CARLOS, Calif., June 28, 2024 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer, submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for lifileucel, a TIL cell therapy, for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. If approved, lifileucel will be the...

OTC Markets Group Welcomes Golden Metal Resources PLC to OTCQX

Written by Customer Service on June 28, 2024. Posted in Public Companies.

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Golden Metal Resources PLC (LON: GMET; OTCQX: GMTLF), a precious and strategic metals exploration company, has qualified to trade on the OTCQX® Best Market. Golden Metal Resources PLC upgraded to OTCQX from the OTCQB® Venture Market. Golden Metal Resources PLC begins trading today on OTCQX under the symbol “GMTLF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate...

Month: June 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice